Physician profile
Benjamin Paul Williams
NPI 1508880352
$10,393.97
in general payments reported to CMS, 2019-2025
50 companies · $1,481 in 2025
The $1,481 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,497 · 2020: $1,136 · 2021: $1,335 · 2022: $1,379 · 2023: $1,633 · 2024: $1,934 · 2025: $1,481.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,048.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,048.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,105.91 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,099.74 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $1,006.31 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $949.65 | 2019-2025 | |
| Abbvie INC. | $506.33 | 2020-2025 | Vraylar |
| Amgen INC. | $406.91 | 2019-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $404.53 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Otsuka America Pharmaceutical, INC. | $321.25 | 2021-2025 | Rexulti, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $311.45 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $281.61 | 2019-2024 | Jardiance |
| Mylan Specialty L.P. | $266.91 | 2019-2024 | Yupelri |
| Edwards Lifesciences Corporation | $230.65 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $230.14 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $188.53 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $172.92 | 2023-2025 | Gemtesa |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.